[1] MOREAU M E,GARBACKI N,MOLINARO G,et al.The kallikrein-kinin system:current and future pharmacological targets[J].J Pharmacol Sci,2005,99:6-38.
[2] HECQUET C,TAN F,MARCIC B M,et al.Human bradykinin B(2)receptor is activated by kallikrein and other serine proteases[J].Mol Pharmacol,2000,58:828-836.
[3] CHAO J,BLEDSOE G,YIN H,et al.The tissue kallikrein-kinin systemprotects against cardiovascular and renal diseases and ischemicstroke independently of blood pressure reduction[J].Biol Chem,2006,387:665-675.
[4] REGOLI D,RHALEB N E,DRAPEAU G,et al.Kinin receptor subtypes[J].J Cardiovasc Pharmacol,1990,15(Suppl 6):S30-S38.
[5] GREENBAUM L M.T-kinin and T-kininogen-children of new technology[J].Biochem Pharmacol,1984,33:2943-2944.
[6] OKAMOTO H,GREENBAUM L M.Pharmacological properties of T-kinin[J].Biochem Pharmacol,1983,32:2637-2638.
[7] NUSTAD K K,VAAJE K,PIERCE J V.Synthesis of kallikrein by rat kidneyslices[J].Br J Pharmacol,1975,53:229-234.
[8] SHARMA J N,ZEITLIN I J,DEODHAR S D,et al.Detection oftissue kallikrein-like activity in inflamed synovial tissue[J].Arch Int Pharmacody Ther,1983,262:279-286.
[9] NOLLY H L,BROTIS J.Kinin-forming enzyme in rat cardiac tissue[J].Am J Physiol,1981,265:H1209-1214.
[10] SHARMA J N,UMA K.Cardiac kallikrein in hypertensive and diabetic rats with and without diabetes[J].Immunopharmacology,1996,33:341-343.
[11] SHARMA J N,UMA K,YUSOF A P.Left ventricular hypertrophy and itsrelation to the cardiac kinin-forming system in hypertensive and diabetic rats[J].Int J Cardiol,1998,63:229-235.
[12] BHOOLA K D,FIGUEROA C D,WORTH K.Bioregulation of kinin,kallikrein,kininogen and kininases[J].Pharmacol Rev,1992,44:1-80.
[13] TAKADA Y,SKIDGEL R A,ERDOS E G.Purification of human urinary prokallikrein:identification of the site of activation by the metalloproteinasethermolysin[J].Biochem J,1985,232:851-856.
[14] WEISS A S,GALLIN J L,KAPLAN A P.Fletcher factor deficiency:a diminishedrate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation,fibrinolysis,chemotactic activity and kinin generation[J].J Clin Invest,1974,53:622-633.
[15] COCHRANE C G,REVAK S D,WUEPPER D.Activation of Hageman factor in solid and fluid phase.A critical role of kallikrein[J].Exp Med,1973,138:1564-1583.
[16] GRIFFIN J H,COCHRANE C G.Mechanism for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor[J].Proc Natl Acad Sci USA,1976,73:2554-2558.
[17] MANDLE R,COLMAN R W,KAPLAN A.Identification of prekallikrein and HMW-kininogen as a complex in human plasma[J].Proc Natl Acad Sci USA,1976,73:4176-4183.
[18] THAMPSON R E,MANDLE R,KAPLAN A P.Association of factor Ⅸ and high molecular weight kininogen in human plasma[J].J Clin Invest,1977,60:1376-1380.
[19] SILVERBERG M,DIEHL S.The autoactivation of factor Ⅻ(Hageman factor) induced by low-heparin and dextran sulfate[J].Biochem J,1987,248:715-720.
[20] CHAO J,CHAO L.Kallikrein-kinin in stroke,cardiovascular and renal disease[J].Exp Physiol,2005,90:291-298.
[21] ZHAO C,WANG P,XIAO X,et al.Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructoseinduced hypertensive rats[J].Hypertension,2003,42:1026-1033.
[22] LING L,HOU Q,XING S,et al.Exogenous kallikrein enhances neurogenesis and angiogenesis in the subventricular zone and the peri-infarction region and improves neurological function after focal cortical infarction in hypertensive rats[J].Brain Res,2008,1206:89-97.
[23] YUAN G,DENG J,WANG T,et al.Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 50-monophosphate-activated protein kinase signaling pathways[J].Endocrinology,2007,148:2016-2026.
[24] SHARMA J N.Interrelationship between the kallikrein-kinin system and hypertension:a review[J].Gen Pharmacol,1988,19:177-187.
[25] SHARMA J N,UMA K K,NOOR A R.Blood pressure regulation by the kallikrein-kinin system[J].Gen Pharmacol,1996,27:55-63.
[26] De FREITAS F M,FARRACO E Z,De AZEVEDO D F.General circulatory alterations induced by intravenous infusion of synthetic bradykinin in man[J].Circulation,1964,29:66-70.
[27] WEBSTER M E,GILMORE J P.Influence of kallidin-10 on renal function[J].Am J Physiol,1964,206:714-718.
[28] McGIFF J C,ITSKOVITZ H D,TERRANGO N A.The action of bradykinin and eledoicin in the canine isolated kidney:relationship to prostaglandins[J].Clin Sci Mol Med,1975,49:125-131.
[29] MARGOLIUS H S,GELLER R,PISANO J J,et al.Altered urinary kallikrein excretion in human hypertension[J].Lancet,1971,2:1063-1065.
[30] MARGOLIUS H S,GELLER R,DEJONG W,et al.Altered urinary kallikrein excretion in rats with hypertension[J].Circ Res,1972,30:358-362.
[31] SHARMA J N,ZEITLIN I J.Altered plasma kininogen in clinical hypertension[J].Lancet,1981,1:125-126.
[32] SHARMA J N.Kinin system and prostaglandins in the intestine[J].Pharmacol Toxicol,1988,63:310-316.
[33] ALMEIDA F A,STELLA R C,VOOS A,et al.Malignant hypertension:a syndrome associated with low plasma kininogen and kinin potentiating factor[J].Hypertension,1981,3:46-50.
[34] JAMES F W,DONALDSON V H.Decrease exercise tolerance and hypertension in serve hereditary deficiency of plasma kininogen[J].Lancet,1981,1:889.
[35] KATORI M,MAJIMA M.Role of the renal kallikrien-kinin system in the development of hypertension[J].Immunophar-macology,1997,36:237-242.
[36] WANG C,CHAO L,CHAO J.Human tissue kallikrein induces hypotension in transgenic mice[J].Hypertension,1994,23:236-243.
[37] SHARMA J N,AMRAH S S,NOOR A R.Suppression of hypotensive responses of captopril and enalapril by kallikrein inhibitors aprotinin in spontaneously hypertensive rats[J].Pharmacology,1995,50:363-369.
[38] CHAO J,CHAO L.Kallikrein gene therapy in hypertension,cardiovascular and renal diseases[J].Gen Ther Mol Biol,1998,1:301-308.
[39] SILBERBAUER K,STANEK B,TEMPLE H.Acute hypotensive effect of captopril in man modified by prostaglandian synthesis inhibition[J].Br J Clin Pharmacol,1982,14:87S-93S.
[40] ANTONACCIO M.Angiotensin converting enzyme(ACE) inhibitors[J].Annu Rev Pharmacol Toxicol,1982,22:57-87.
[41] SHARMA J N,FERANDEZ P G,KIM B K,et al.Systolic blood pressure responses to enalapril maleate(MK 421),an angiotensin converting enzyme inhibitor and hydrochlorothiazide in conscious Dahl salt-sensitive(S) and salt-resistant(R) rats[J].Can J Physiol Pharmacol,1984,62:241-243.
[42] EDERY H,ROSENTHAL T,AMITZUR G,et al.The influence of SQ 20881 on the blood kinin system of renal hypertensive patients[J].Drug Exp Clin Res,1981,Ⅶ:749-756.
[43] LINZ W,WIEMER G,GOHLKE P.Contribution of kinin to the cardiovascular action of converting-enzyme inhibitors[J].Pharmacol Rev,1995,47:25-50.
[44] ZHU P,ZUGGA C E,SIMPER D,et al.Bradykinin improves postischaemic recovery in the rat heart:role of high energy phosphates,nitric oxide and prostacyclin[J].Cardiovasc Res,1995,29:658-663.
[45] SHARAM J N,KESAVARAO U,YUSOF A P.Altered cardiac tissue and plasma kininogen levels in hypertensive and diabetic rats[J].Immunopharmacology,1999,43:129-132.
[46] MADEDDU P,MILIA A F,SALIS M B,et al.Renovascular hypertension in bradykinin B2-receptor knockout mice[J].Hypertension,1998,23:305-509.
[47] KICHUCK M R,SEYEDI N,ZHANG X,et al.Regulation of nitric acid production in human coronary microvessels and the contribution of local kinin formation[J].Circulation,1996,94:44-51.
[48] WHALLEY E T,SOLOMON J A,MODAFFERI D M.CP-0127,a novel potent bradykinin antagonist increases survival in rat and rabbit model of endotoxin shock[J].Agents Actions,1992,38(Suppl):413-420.
[49] KOIDE A,ZEITLIN I J,PARRATT J R.Kinin formation in ischaemic heart and aorta of anaesthetized rats[J].J Physiol(Lond),1993,467:125P.
[50] SCHOLKENS B A.Kinins in the cardiovascular system[J].Immunopharmacology,1996,33:209-217.
[51] LINZ W,WIEMER G,SCHOLKENS B A.Bradykinin prevents left ventricular hypertrophy in rats[J].J Hypertens,1993,11(Suppl 5):S96-97.
[52] VEGH A,SZEKERES L,PARRATT J R.Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmia in anaesthetized dogs[J].Br J Pharmacol,1991,104:294-295.
[53] WALLS T M,SHEEHY R,HARTMAN J C.Role of bradykinin in myocardial preconditioning[J].J Pharmacol Exp Ther,1994,270:681-689.
[54] RUBIN L E,LEVI R.Protective role of bradykinin in cardiac anaphylaxis[J].Circ Res,1995,79:434-440.
[55] YOSHIDA H,ZHANG J J,CHAO L,et al.Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischaemia and perfusion[J].Hypertension,2000,35:25-31.
[56] SHARMA J N,KESAVARAO U.Effect of captopril on urinary kallikrein,blood pressure and myocardial hypertrophy in diabetic spontaneously hypertensive rats[J].Pharmacology,2002,64:196-200.
[57] DELA C R,SUFFREDINI A,PAGE J D,et al.Activation of kallikrein-kinin system after endotoxin administration to normal human volunteers[J].Blood,1993,81:3313-3317.
[58] ABBAS S A,SHARMA J N,YUSOF A P.The effect of bradykinin and its antagonist on survival time after coronary artery occlusion in hypertensive rats[J].Immunopharmacology,1999,44:93-98.
[59] GRIOL-CHARHBILI V,MESSADI-LARIBI E,BASCANDS J L,et al.Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia[J].FASEB J,2005,19(9):1172-1174.
[60] ABBAS S A,SHARMA J N,YUSOF A P.Effect of bradykinin and its antagonist on survival time after coronary artery occlusion in rats[J].Gen Pharmacol,1999,33:243-247.
[61] ABBAS S A,SHARMA J N,YUSOF A P.The effect of bradykinin and its antagonist on survival time after coronary artery occlusion in hypertensive rats[J].Immunopharmacology,1999,44:93-98.
[62] YUYU Y,ZULONG S,YEFEI L,et al.Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity[J].Hum Gene Ther,2012,23:859-870.
[63] NICOLLE K,RAJESH G K,MAURO S.Role of Kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential[J].Circ Res,2008,103(11):1335-1343.
[64] LINZ W W,WIEMER G,SCHOLKENS B A.Contribution of bradykinin to the cardiovascular effects of ramipril[J].J Cardiovasc Pharmacol,1993,22(Suppl 9):S1-8.
[65] SHARMA J N,UMA K,YUSOF A P.Altered cardiac tissue and plasma kininogen levels in hypertensive and diabetic rats[J].Immunopharmacology,1999,34:129-132.
[66] NIES A S,FORSYTH R P,WILLIAMS H E,et al.Contribution of kinins to endotoxin volunteers[J].Blood,1993,81:3313-3317.
[67] MARCONDES S,ANTUNES E.The plasma and tissue kinino-gen-kallikreinkinin system:role in cardiovascular system[J].Curr Med Chem,2005,3:33-44.
[68] MAESTRI R,MILIA A F,SALIS M B,et al.Cardiac hypertrophy and microvascular deficit in Kinin B2 receptor knockout mice[J].Hypertension,2003,41:1151-1155.
[69] KONSTANTINOS S,DIRK W,HEINZ-PETER S,et al.Kinins in cardiac inflammation and regeneration:insights from ischemic and diabetic cardiomyopathy[J].Neuropeptides,2010,44:119-125.
[70] ZHANG J J,CHAO L,CHAO J.Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats[J].Stroke,1999,30:1925-1931;discussion 1931-1932.
[71] XIA C F,YIN H,BORLONGAN C V,et al.Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis[J].Hypertension,2004,43:452-459.
[72] XIA C F,YIN H,YAO Y Y,et al.Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis[J].Hum Gene Ther,2006,17:206-219. |
